INTRODUCTION {#S5}
============

Necrotizing enterocolitis (NEC) can be a life-threatening disorder and we need more accurate ways to recognize cases during its earliest stages ([@R1]-[@R4]). When the initial x-rays are inconclusive, we typically stop the feedings, initiate antibiotics and parenteral nutrition, and order serial abdominal x-rays ([@R5]). If a reliable way were available to confirm the diagnosis of NEC at the onset of abdominal distention when x-rays are not diagnostic, that information could help guide the course of treatment ([@R5]).

Calprotectin is an antibacterial protein found in neutrophils, monocytes, and macrophages. It constitutes approximately 60% of the cytosolic proteins of neutrophils ([@R6]-[@R8]). Calprotectin binds to calcium, stabilizing it and preventing degradation in the intestine ([@R9]). Adults with inflammatory bowel disorders have high stool calprotectin concentrations ([@R6]-[@R12]). High levels of calprotectin in stool is likely from migration of activated neutrophils across gastrointestinal epithelial membranes ([@R11]). Previous studies report higher calprotectin levels in stools of neonates with NEC, compared with stools of healthy control neonates ([@R8], [@R10], [@R13]-[@R25]). However, it is not clear whether measuring stool calprotectin at the onset of intestinal signs would discriminate between cases that are eventually going to be diagnosed as NEC *vs.* more benign forms of feeding intolerance. We prospectively tested this possibility.

As part of this study, we also investigated the source of calprotectin in the intestine of neonates with NEC. Calprotectin is located within neutrophils. As part of the innate immune response, neutrophils can eject nuclear chromatin and bactericidal proteins known as neutrophil extracellular traps (NETs) to trap and kill microorganisms ([@R26], [@R27]). NETs contain calprotectin ([@R28]). We sought to further define the relationship between calprotectin and NETs in bowel tissue from neonates with NEC.

METHODS {#S6}
=======

Study Design and Populations {#S7}
----------------------------

This was a prospective pilot study conducted in two Intermountain Healthcare NICUs; McKay-Dee Hospital, Ogden, UT and Utah Valley Regional Medical Center, Provo, UT. The Intermountain Healthcare Institutional Review Board approved the protocol and an informed consent document was signed by the parents of all participating neonates. Intermountain Healthcare is a not-for-profit system that owns and operates 22 hospitals in Utah and Idaho. IRB approval for the calprotectin immunohistochemical and immunocytochemical experiments with analysis of NETosis was obtained through the University of Utah. The University of Utah IRB classified this study as exempt from requiring signed consent because of the deidentified status of the tissues.

When a clinician ordered an abdominal x-ray to "rule out NEC" the neonate was considered eligible for this study. Any stools at the time of the x-ray, or preceding the x-ray by \<2 hours, or within the 12 hour period following the x-ray, were placed in a special stool-collection vial (minimum one gram) for calprotectin analysis as a research study. Parents were contacted within several hours of the qualifying x-ray and told of the study. If the parents consented, the stool was submitted to ARUP laboratories for fecal calprotectin assay. If the parents refused, the stool was discarded. For consented patients, a repeat stool sample was also sent for calprotectin assay within 72 hours of the qualifying x-ray. If a second stool was not passed by 72 hours, the next-passed stool was used and the time recorded. The fecal calprotectin tests were not billed to families or third-party payers, but were paid by a research grant. The calprotectin levels were not placed in the medical record or reported to the clinicians.

This was a convenience sample of 30 episodes of "rule-out NEC". Thirty episodes was selected on the basis of the funding available for the study. Patients were only entered into the protocol when a study nurse or study neonatologist was available to explain the study and provide informed consent for parents. The research did not involve ordering any other laboratory tests or x-rays; however clinically indicated blood tests and x-rays, physical examination findings, and clinical decisions on the study patients were available to the research team and included in the study analysis.

During the study period the two NICUs had a consistent clinical approach which included: feeding mother\'s own milk or pasteurized human milk ([@R29]); using restrictive erythrocyte transfusion guidelines ([@R30]); using delayed cord clamping or cord milking for preterm delivery ([@R31]); obtaining the initial laboratory blood work from otherwise discarded fetal blood in the umbilical cord ([@R32]); and not providing enteral feedings during blood transfusions.

One week or more following the study entry, study staff assembled all relevant clinical and research data, including the diagnosis arrived at by the clinicians regarding the cause of the abdominal distention. Causes were categorized by the research staff, as shown in [Table 1](#T1){ref-type="table"}, as either; not NEC (with hematochezia or without hematochezia), Medical NEC (Stage II), or Surgical NEC (Stage III). Cases were evaluated for the possibility of misdiagnosis, i.e. for spontaneous intestinal perforation as a potential confounding diagnosis.

Calprotectin assay {#S8}
------------------

The PhiCal fecal calprotectin immunoassay (Genova Diagnostics, Inc. Ashville, NC) is an enzyme-linked immunoassay system with colorimetric detection, and was performed at ARUP laboratories (Salt Lake City, UT) according to the manufactures instructions. The test uses a polyclonal antibody against calprotectin. Calprotectin present in the diluted sample is bound by the antibody absorbed to the surface of the plastic well. The enzyme conjugated antibody binds to the captured antigen and subsequently the enzyme catalyzes the conversion of the substrate to a colored product. The intensity of the color is proportional to the amount of conjugate bound, and thus to the amount of captured calprotectin. Concentration of calprotectin in the samples is calculated using a standard, provided in the test kit.

Localization of calprotectin to neutrophil extracellular traps {#S9}
--------------------------------------------------------------

PMNs were isolated from ACD or EDTA anticoagulated venous blood from healthy adults under protocols approved by the University of Utah IRB. PMN suspensions (\> 96% pure) were prepared by positive immunoselection using anti-CD15-coated microbeads and an auto-MACS cell sorter (Miltenyi Biotec, Inc.) and were resuspended at 2 × 10^6^ cells/mL concentration in serum-free M-199 media at 37° C in 5% CO~2~/95% air. Qualitative assessment of NET formation was performed as previously reported ([@R26], [@R33]). Briefly, primary PMNs isolated from healthy adults (2 × 10^6^ cells/mL) were incubated with control buffer or stimulated with LPS (100 ng/mL) for 1 hour at 37°C in 5% CO~2~/95% air on glass coverslips coated with poly-L-lysine. After stimulation, PMNs were gently washed with PBS and fixed with 4% p-FA for 10 minutes followed by permeabilization with Triton-X100 for 10 minutes. Calprotectin protein expression was detected via immunocytochemistry using a FITC-conjugated anti-human calprotectin primary antibody (LifeSpan BioSciences, 1:100 dilution). Confocal microscopy was accomplished using a FV1000 1X81 confocal Microscope and FluoView software (Olympus). Both 20X and 60X objectives were used. Z-series images were obtained at a step size 1μm over a range of 20μm for each field. Olympus FluoView and Adobe Photoshop CS software were used for image processing.

Localization of calprotectin within the bowel of neonates with NEC {#S10}
------------------------------------------------------------------

Gastrointestinal tissue samples from surgically treated prematurely born neonates with NEC (n=5) were compared using immunohistochemical techniques to gastrointestinal tissue samples processed in parallel from control patients operated on for indications other than NEC (n=6). Immunohistochemistry on paraffin sections followed established procedures, including de-waxing, rehydration, and high temperature antigen retrieval (Vector Unmasking Solution, Vector Laboratories, Burlingame, CA) prior to blocking. Primary antibodies utilized in this study were as follows: anti-human Calprotectin (LifeSpan Biosciences, 1:100 dilution); anti-human Neutrophil Elastase (Hycult, 1:100 dilution). An Alexa-568 goat anti-rabbit secondary antibody (Molecular Probes, 1:1000 dilution) was used. Prior to imaging via confocal microscopy, tissue sections were incubated with DRAQ5 (Cell Signaling, 1:1000 dilution) as a DNA counterstain. Confocal microscopy was accomplished as described previously for immunocytochemistry ([@R26], [@R33]).

Statistical Analysis {#S11}
--------------------

The program used for data collection was a modified subsystem of Clinical Workstation. The 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. Data were managed and accessed by authorized data analysts. Means and standard deviations were used to express values in groups that were normally distributed, and medians and interquartile ranges to express values in groups that were not. Differences in categorical variables were assessed using the Fisher exact test or chi-square for normally distributed data and Tukey\'s bi-weight estimator for groups that were not. Statistical analysis used Statit (Midas, Tucson, AZ). Statistical significance was set as *p* \<0.05. The statistical performance of fecal calprotectin was also assessed by receiver operating characteristic (ROC) curves (IBM SPSS Statistics, Version 23.0, Armonk, NY).

RESULTS {#S12}
=======

We initiated study enrollment at McKay-Dee Hospital, Ogden, Utah, in May 2014 and at Utah Valley Regional Medical Center, Provo, Utah, in June 2014, and concluded in July 2015. As diagramed in [Figure 1](#F1){ref-type="fig"}, 31 episodes qualified for the study at a time when study-personnel were available to ask parents for study consent. Parental consent was obtained for 30. [Figure 1](#F1){ref-type="fig"} shows study enrollment, procedures, and the eventual clinical diagnosis made for each of the 30 "rule-out NEC" episodes. There were no cases of spontaneous intestinal perforation.

The paired (initial and follow-up) fecal calprotectin levels of the 30 episodes are shown in [Figure 2](#F2){ref-type="fig"}. Calprotectin levels were higher in the first-sample stools of the 15 with NEC (median 516 μg/g stool; 1^st^ quartile 226 μg/g; 3^rd^ quartile 797 μg/g) than in the 15 who turned out not to have NEC (median 110 μg/g; 1^st^ quartile 39 μg/g; 3^rd^ quartile 165 μg/g; *p*\<0.00001). Calprotectin levels were also higher in the second-sample stools of the 15 with NEC (372 μg/g stool, 1^st^ quartile 135 μg/g; 3^rd^ quartile 1175 μg/g) than in the 15 who did not have NEC (54 μg/g; 1^st^ quartile 28 μg/g; 3^rd^ quartile 103 μg/g, *p*\<0.0001). The time to passage of the second stool was similar in the 15 who did not have NEC (92±62 hours) and in the 15 who did (100±66 hours, p\<0.665).

Clinical and laboratory findings during the week following the qualifying X-ray are shown in [Table 2](#T2){ref-type="table"}. All 15 who were retrospectively judged as having had NEC received antibiotics for ≥ 5 days and were labeled as having NEC in the medical record. None of the 15 judged as not having had NEC had an x-ray showing pneumatosis, portal venous gas, or perforation, and none had thrombocytopenia or neutropenia, or antibiotics for ≥5 days, and none were labeled as having NEC in the medical record.

Ten of the 15 neonates with NEC had a fall in fecal calprotectin between their first-studied stool (655±369 pg/g) and their second-studied stool (327±368 pg/g). The other five had an increase, from (331±214 pg/g in the first stool to 1086±299 pg/g in the second; [figure 2](#F2){ref-type="fig"}, dashed lines). The 10 where it fell and the 5 where it increased were of similar gestational age at birth (p=0.55), birth weight (p=0.39), corrected age at the time the "rule-out NEC" x-ray was taken (p=0.49), and length of time between the initial and follow-up stool (p=0.42). However in all six with the highest initial calprotectin, the subsequent level fell. The five where the level went up had a lower initial value than those where the level fell (p\<0.0001).

In the 15 that did not have NEC, bloody stools did not significantly elevate the fecal calprotectin level. Hematochezia (n=6) (median 101 μg/g stool; 1^st^ quartile 39 μg/g, 3^rd^ quartile 168 μg/g); no hematochezia (n=9) (median 54 μg/g stool; 1^st^ quartile 21 μg/g; 3^rd^ quartile 116 μg/g; *p* = 0.074).

Demographic, clinical, and laboratory information describing the neonates at the onset of their "rule-out NEC" episode are shown in [Table 2](#T2){ref-type="table"}. None of the 15 episodes of NEC, and none of the 15 episodes that were not NEC, had a blood transfusion in the preceding 48 hours. The group of 15 with NEC were of similar birth weight, gestational age, gender, race, and postnatal age as the 15 who turned out not to have NEC. CBC values obtained with the qualifying x-ray as part of the "rule out NEC" evaluation, and any CBC value obtained within 24 hours before that evaluation, are included in [Table 2](#T2){ref-type="table"}. In the 15 who had NEC the I/T neutrophil ratios were slightly higher (p=0.046) and stool calprotectin levels significantly higher (*p*\<0.0001).

[Table 3](#T3){ref-type="table"} shows laboratory information within the 4-days following the "rule out NEC" xray. The one patient with surgical NEC had the highest and also the lowest leukocyte counts of the group, the highest I/T neutrophil ratio, and the lowest monocyte and platelet counts. The 15 with NEC had higher follow-up stool calprotectin levels than did the 15 who did not have NEC (p\<0.0001).

[Figure 3](#F3){ref-type="fig"} shows ROC analysis, showing curves for both the initial and the follow-up stool levels of calprotectin.

Using immunohistochemistry, calprotectin in bowel excised from neonates with NEC was associated with activated neutrophils in neutrophil extracellular traps. [Figure 4A](#F4){ref-type="fig"} demonstrates NET-associated calprotectin in intestinal tissue obtained from neonates treated surgically for NEC (n= 5 different neonates). Parallel analysis of intestinal tissue samples from control newborn infants who underwent surgical treatment for issues other than NEC (n=6 different neonates) showed no NET formation and no increase in calprotectin protein expression. Immunocytochemical analysis of LPS-stimulated PMNs isolated from healthy adults also demonstrated robust NET formation in vitro with a clear association of calprotectin with NETs ([Figure 4B](#F4){ref-type="fig"}).

DISCUSSION {#S13}
==========

When a NICU patient has abdominal distention or other findings that could suggest a diagnosis of NEC, it is sometimes difficult to know if the condition is indeed NEC or is a less pernicious variety of bowel dysfunction. If the initial x-ray shows pneumatosis or portal venous air, a diagnosis of NEC can be straight forward. However, many times the initial radiograph is not definitive and clinicians must devise a plan for treatment without certainty as to whether or not the patient has NEC.

Certain CBC changes can help identify the condition as NEC ([@R34]). These include thrombocytopenia, disturbance in coagulation, anemia, neutrophilia or neutropenia, and a leukocyte "left shift" ([@R34]-[@R36]). However, we observed relatively minimal CBC changes early in the course of NEC, consistent with a recent report of Maheshwari *et al*. who reported that inflammatory cytokines did not generally rise until after the onset of NEC ([@R37]). Thuijls *et al*. also found that at the onset of suspicion for NEC, the platelet count and CRP were not different between those who were eventually diagnosed with NEC *vs* those with other diagnoses ([@R15]).

In 12 of 13 previous studies, neonates with established NEC had higher stool calprotectin levels than healthy controls \[8, 13-25 and [Supplemental Material](#SD3){ref-type="supplementary-material"}\]. We designed the present study as distinctly different than all previous reports. Specifically, we did not study neonates with well-established NEC, nor did we study healthy controls. Rather, we examined NICU patients at the onset of intestinal pathology sufficient to warrant an abdominal x-ray to "rule-out NEC", and we asked whether the level of calprotectin in the stool at that time could differentiate between those who would go on to a diagnosis of NEC from those who would have a less severe form of feeding intolerance.

Calprotectin is present within neutrophils and is likely to be associated with activated macrophages in the bowel, as suggested by the work of Maheshwari ([@R37], [@R37], [@R39]). Neutrophils use several antibacterial modalities including degranulation and phagocytosis. In 2004, Brinkmann *et al.* reported a different mechanism; the ejection of nuclear chromatin and bactericidal proteins in a structure known as neutrophil extracellular traps (NET) to ensnare and kill microorganisms ([@R40]). The process has been termed NETosis ([@R41]). We found that calprotectin in excised NEC-affected bowel is one of the proteins released by neutrophils in association with NETs. Thus, at least some of the calprotectin in stools of neonates with NEC is derived from activated neutrophils migrating to the bowel mucosa and lumen and exporting antimicrobial calprotectin by way of NETosis.

We found that at the onset of abdominal distension that raised a concern for NEC, a higher calprotectin level was indicative of NEC. Hematochezia did not significantly increase the calprotectin level. This is consistent with the observation in adult patients that gastrointestinal bleeding of as much as 100 mL per day increases the fecal calprotectin concentration by only 15 μg/g \[ARUP Laboratories <http://ltd.aruplab.com/Tests/Pub/0092303>\]. Thus, perhaps a fecal calprotectin level can be of value, in questionable cases, in initially planning the length of NPO, TPN, and antibiotics, and in discussions with the family and staff.

We recognize limitations of our study. It is a pilot report involving only 30 episodes. We investigated infants with gastrointestinal signs that prompted a "r/o NEC" x-ray, and therefore we cannot determine a normal fecal calprotectin reference interval from our data. Fecal calprotectin levels are generally higher in neonates than in older children and adults ^6^, and the levels have inter and intra-individual variability based on gestational age, postnatal age, and time of day collected ([@R11], [@R12], [@R14], [@R16]). Thus, creating reference intervals for fecal calprotectin in neonates will be more complex than in older children or adults. Due to a low rate of surgical NEC in the patients in this study, the stool samples measured for calprotectin and the tissue samples assayed for NETs were obtained from different patients. The one case of surgical NEC occurred prior to our investigation into the source of fecal calprotectin which prevented us from using that patient\'s tissue sample. We realize that our evidence that calprotectin in stool originates from activated neutrophils is limited and correlative. However it is the first such evidence in neonates with NEC.

In conclusion, we present pilot data that a fecal calprotectin level at the time of concern for NEC could help distinguish NEC from more benign forms of feeding intolerance. Larger studies are needed to confirm this, and gestational-age and postnatal-age reference ranges for fecal calprotectin are also needed.
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![Flow diagram for the study of episodes of "rule-out NEC".](nihms-775492-f0001){#F1}

![Stool calprotectin levels in 30 episodes of "Rule-out NEC". Time "0" is the time the x-ray was obtained to "rule-out NEC". Paired follow-up levels of stools passed after the qualifying x-ray are connected by dashed (NEC) or solid (Not NEC) lines. One week or more after the qualifying "rule out NEC" x-ray, each of the 30 episodes was assigned as most likely having been due NEC or Not NEC.](nihms-775492-f0002){#F2}

![ROC curves for initial and follow-up fecal calprotectin levels. The initial fecal calprotectin levels are represented by the solid line, and the follow-up calprotectin levels are represented by the dashed line. Area under the curve: 0.942 (95% confidence interval 0.864-1.000) for the initial fecal calprotectin and 0.871 (95% confidence interval 0.729-1.000) for the follow-up level.](nihms-775492-f0003){#F3}

![NETs contribute to intestinal injury associated with NEC and are decorated with calprotectin protein\
(**A**) We used immunohistochemical techniques to compare calprotectin protein expression in gastrointestinal tissue samples collected from 5 different infants who underwent surgical treatment for NEC and 6 control infants operated on for indications other than NEC. Representative images of each are shown. Calprotectin is seen in gold fluorescence. Neutrophil elastase, a protein known to be expressed on NETs, is seen in magenta fluorescence. Nuclear and NET-associated DNA is shown in blue fluorescence. A NET is seen in the intestinal tissue of an infant with NEC (arrows), while no NETs or neutrophil elastase staining were seen in the control tissues. The magnified image of the highlighted box, complete with the three separate fluorescent channel images, demonstrate neutrophil elastase, DNA, and calprotectin staining consistent with NET formation. The images highlighting DNA and neutrophil elastase have been brought up to brighter exposures for the purpose of clearer demonstration. (**B**) NET formation was detected using immunocytochemistry with the same primary antibodies used to detect calprotectin and DNA employed in panel **A**. Freshly isolated adult PMNs were treated with LPS (100 ng/mL) for 1 hour to stimulate NET formation. Again, gold fluorescence denotes calprotectin protein expression and blue fluorescence denotes DNA. These images are representative of 6 different replicates using PMNs isolated from 6 different healthy adults. Bar, 20μm on **A** row 1, images 1 and 2, 5μm on **A** row 1, image 3 and row 2, and 10μm on **B**.](nihms-775492-f0004){#F4}

###### 

Each of 30 episodes of "rule-out NEC" were judged, one week or more after the onset of the qualifying x-ray, as having been due to one of the four categories below.

  Category   Final Diagnosis                                                                           Radiological Signs                                      Typical Intestinal Signs                                                                         Typical Systemic Signs                                                                    Treatment
  ---------- ----------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- --------------------------------------
  **1**      ***NOT NEC - Feeding intolerance*** no hematochezia                                       Normal or dilated loops, no pneumatosis or portal air   Abdominal distention and visible bowel loops                                                     Apnea, bradycardia, lethargy                                                              Antibiotics and NPO period ≤ 2 days
  **2**      ***NOT NEC - Feeding intolerance*** with hematochezia                                     Normal or dilated loops, no pneumatosis or portal air   Abdominal distention and visible bowel loops and hematochezia                                    Apnea, bradycardia, lethargy                                                              Antibiotics and NPO period ≤ 2 days
  **3**      ***Medical NEC stage II*** (surgical procedure not performed)                             Dilated loops, pneumatosis or portal air                Abdominal distention, visible bowel loops, apparent abdominal tenderness, ileus ± hematochezia   Apnea, bradycardia, lethargy, ± acidosis, hypotension, neutropenia, thrombocytopenia      Antibiotics and NPO period \> 5 days
  **4**      ***Surgical NEC stage III*** (surgical procedure performed or death from fulminant NEC)   Dilated loops, pneumatosis or portal air                Signs of peritonitis, marked tenderness, abdominal distention, ileus ± hematochezia              Apnea, bradycardia, lethargy, with acidosis, hypotension, neutropenia, thrombocytopenia   Antibiotics and NPO period \> 5 days

###### 

At the *onset* of each of 30 "rule-out NEC" episodes, x-rays were not diagnostic of NEC (no pneumatosis or portal air or perforation), because this study focused only on cases where NEC was possible but [not definite]{.ul} at the onset. One week after the episode began, each case was judged retrospectively as having been due to NEC, or not having been due to NEC, on the basis of the elements in [table 1](#T1){ref-type="table"} (note: fecal calprotectin level was not used in this judgement, as it was not available to clinicians).

  Findings following the "rule-out NEC" episode                  NEC (n=15)   Not NEC (n=15)
  -------------------------------------------------------------- ------------ ----------------
  Pneumatosis intestinalis^[\*](#TFN1){ref-type="table-fn"}^     8/15         0/15
  Portal venous gas^[\*](#TFN1){ref-type="table-fn"}^            1/15         0/15
  Peritoneal gas^[\*](#TFN1){ref-type="table-fn"}^               1/15         0/15
  Post-NEC bowel stricture^[\*\*](#TFN2){ref-type="table-fn"}^   1/15         0/15
  Thrombocytopenia (\<150,000/μL)                                4/15         0/15
  Neutropenia (\<1000/μL)                                        3/15         0/15
  Duration of antibiotics ≥5 days                                15/15        0/15
  Diagnosis of NEC by attending neonatologist                    15/15        0/15

Pneumatosis was first observed on a repeat x-ray taken in 8 neonates at the following times (hours after the initial qualifying x-ray); 2h, 3h, 6h, 24h, 24h, 24h, 24h, and 72h. Portal venous gas was diagnosed in one neonate 24 hours after the qualifying x-ray. Free intraperitoneal air was found in one neonate 24 hours after the qualifying x-ray.

A post-NEC ileal stricture was identified 4 weeks after the qualifying "rule-out NEC" episode.

###### 

AT THE BEGINNING OF THE "RULE OUT NEC" EPISODE. Demographic features, selected laboratory values, and fecal calprotectin levels at the onset of 30 episodes of "rule out NEC" evaluations.

                                            EVENTUAL DIAGNOSIS OF THE "RULE-OUT NEC" EPISODE                                             
  ----------------------------------------- -------------------------------------------------- ------------- ------------- ------------- -------
  Birth weight (grams)                      1239 ± 932                                         1699 ± 417    1289 ± 555    3550          0.924
  Gestational age at birth (weeks ± days)   28 ± 5                                             31 ± 3        29 ± 3.8      36            0.693
  Gender (% male)                           7/9 (78%)                                          5/6 (83%)     9/14 (64%)    1/1 (100%)    0.410
  Race (% non-white)                        3/9 (33%)                                          0/6 (0%)      1/14 (7%)     0 (0%)        0.283
  Postnatal age at "R/O NEC" (weeks)        32 ± 3                                             33 ± 4        31 ± 9        36            0.384
  Leukocyte count (X10^3^/μL)               11.9 ± 6.4                                         14.8 ± 6.2    11.9 ± 6.2    9.8 ± 5.9     0.480
  I/T neutrophil ratio                      0.10 ± 0.07                                        0.16 ± 0.05   0.18 ± 0.17   0.67 ± 0.26   0.046
  Monocyte count (X10^3^/μL)                1.3 ± 0.8                                          1.9 ± 0.9     1.7 ± 0.9     1.6 ± 1.3     0.987
  Eosinophil count (X10^3^/μL)              0.6 ± 1.0                                          0.7 ± 0.3     0.5 ± 0.4     0.6           0.620
  Platelet count (X10^3^/μL)                232 ± 78                                           284 ± 157     341 ± 82      184 ± 85      0.005
  Stool Calprotectin (μg/g stool)           83 ± 66                                            159 ± 121     567 ± 371     235           0.000

Values are either shown as (mean±SD or median with 1^st^ and 3^rd^ quartile)

###### 

DURING THE THREE-DAY PERIOD FOLLOWING THE ONSET OF THE "RULE OUT NEC" EPISODE. Selected laboratory values, and fecal calprotectin levels following 30 episodes of "rule out NEC".

                                         EVENTUAL DIAGNOSIS OF THE "RULE-OUT NEC" EPISODE                                      
  -------------------------------------- -------------------------------------------------- ------------- ------------- ------ --------
  Highest leukocyte count (X10^3^/μL)    12.1 ± 6.1                                         20.0 ±0.3     13.8 ±5.8     27.4   0.812
  Lowest leukocyte count (X10^3^/μL)     10.0 ± 3.3                                         15.37± 3.9    13.3 ± 5.3    1.1    0.921
  Highest I/T neutrophil ratio           0.05 ± 0.06                                        0.07 ± 0.06   0.16 ± 0.07   0.69   0.055
  Lowest monocyte count (X10^3^/μL)      0.9 ± 0.3                                          2.4 ± 1.1     1.3 ± 1.1     0.3    0.331
  Highest eosinophil count (X10^3^/μL)   0.5 ± 0.6                                          0.5 ± 0.4     0.8 ± 0.3     0.8    0.279
  Lowest platelet count (X10^3^/μL)      224 + 96                                           311 ± 190     310 ± 51      76     0.818
  Highest Calprotectin (μg/g stool)      59 ± 40                                            97 ± 95       526 ± 471     1342   0.0001
